| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vitro |
Azosemide inhibits hNKCC1A and hNKCC1B, the human variants of the sodium-potassium chloride cotransporter[1].
|
|---|---|
| ln Vivo |
Azosemide showed smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NAR[2].
|
| Animal Protocol |
Animal/Disease Models: 9weeks old male SD (SD (Sprague-Dawley)) rat (control rat, body weight 310345 g) and NAR (body weight 220315 g) [2]
Doses: 10 mg/kg (pharmacokinetic/PK/PK analysis) Route of Administration: via the neck intravenous (iv) (iv)infusion over 1 minute (iv) Experimental Results: demonstrated smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase) ), CLR (853% increase) and CLNR NAR (307% increase). |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
In healthy individuals, peak plasma concentrations of azosemide are reached within 3–4 hours after administration on an empty stomach. The absorption delay is approximately 1 hour. Oral bioavailability is estimated at 20.4%. Systemic clearance is 112 ml/min. Renal clearance is 41.6 ml/min. It is actively secreted in the proximal tubules of the human kidney. This may or may not involve nonspecific organic acid secretion pathways. Therefore, disease states and other organic acids that affect organic acid transport pathways (e.g., nonsteroidal anti-inflammatory drugs) may affect the efficacy of azosemide. It has poor affinity for human tissues. The volume of distribution after apparent pseudodistribution is small, at 0.262 l/kg. Metabolism/Metabolites First-pass metabolism is significant; therefore, parenteral administration is more effective than oral administration. Eleven metabolites of azosemide have been found in rats, but only azosemide and its glucuronide have been detected in humans. Biological half-life Terminal half-life: 2-3 hours. |
| Toxicity/Toxicokinetics |
Protein Binding
At azosemil concentrations of 10-100 ug/ml, the binding rate of 95% 4% protein to 4% human serum albumin was determined using balanced dialysis. |
| References |
|
| Additional Infomation |
Azosemide is a sulfonamide drug with the structure benzenesulfonamide, substituted at positions 2, 4, and 5 with chlorine, (2-thiophenemethyl)amino, and 1H-tetrazole-5-yl, respectively. It is a diuretic used to treat edema and hypertension. It is a loop diuretic. It belongs to the tetrazolium, monochlorobenzene, sulfonamide, and thiophene classes of compounds. Azosemide is a loop diuretic used to treat hypertension, edema, and ascites. Azosemide is a monosulfonamide drug, belonging to the loop diuretic class. Azosemide inhibits the reabsorption of sodium and chloride in the thick ascending limb of the loop of Henle. Mechanism of Action: Its exact mechanism of action is not yet clear. However, it primarily acts on the loop of Henle, including the medullary and cortical segments. Pharmacodynamics: The diuretic effect after oral administration is similar to that of furosemide. However, when administered intravenously, alzosenmethoxazole has a diuretic effect 5.5 to 8 times greater than that of furosemide.
|
| Molecular Formula |
C12H11CLN6O2S2
|
|---|---|
| Molecular Weight |
370.8377
|
| Exact Mass |
370.007
|
| CAS # |
27589-33-9
|
| PubChem CID |
2273
|
| Appearance |
White to off-white solid powder
|
| Density |
1.661g/cm3
|
| Boiling Point |
671.1ºC at 760mmHg
|
| Melting Point |
219.5 °C
|
| Flash Point |
359.6ºC
|
| Vapour Pressure |
7.19E-18mmHg at 25°C
|
| Index of Refraction |
1.709
|
| LogP |
3.695
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
504
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HMEDEBAJARCKCT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H11ClN6O2S2/c13-9-5-10(15-6-7-2-1-3-22-7)8(12-16-18-19-17-12)4-11(9)23(14,20)21/h1-5,15H,6H2,(H2,14,20,21)(H,16,17,18,19)
|
| Chemical Name |
2-chloro-5-(2H-tetrazol-5-yl)-4-(thiophen-2-ylmethylamino)benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~674.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6966 mL | 13.4829 mL | 26.9658 mL | |
| 5 mM | 0.5393 mL | 2.6966 mL | 5.3932 mL | |
| 10 mM | 0.2697 mL | 1.3483 mL | 2.6966 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
